A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether methylene blue (MB) is of benefit in treating adult patients who develop catecholamine-resistant vasoplegic syndrome (VPS) during cardiac surgery. Altogether 47 papers were found in Medline and 107 in Embase using the reported search. A further five papers were found by handsearching reference lists. Four papers represented the best evidence on the subject and details of authors, journal, date and country of publication, patient group, relevant outcomes and weaknesses were tabulated. In addition, a further 14 papers are referenced to aid the discussion. We conclude that MB may provide an interesting and novel therapeutic option for adult patients who develop catecholamineresistant VPS during cardiac surgery. Whilst there is currently insufficient evidence to advocate its use as first-line therapy it should be considered as a possible 'rescue therapy' in catecholamine-resistant VPS and some work has suggested that it may have a prophylactic role in preventing VPS. However, further large well-controlled studies are required before its routine use can be recommended.
Introduction
A best evidence topic was constructed according to a structured protocol. This protocol is fully described in the ICVTS w1x.
The three-part question
In wadult patients undergoing cardiac surgeryx is wMethylene Bluex of benefit in treating wvasoplegic syndromex.
Clinical scenario
You are performing urgent CABG surgery on a 56-year-old lady. She becomes profoundly hypotensive, unresponsive to traditional vasoconstrictors and catecholamines during cardiopulmonary bypass. One of your colleagues tells you that he has used methylene blue as a vasoconstrictor in such vasoplegic patients. You wonder if there is any evidence to support this observation. E-mail address: prbevora@netsite.com.br (P.R.B. Evora). 
Search strategy

Search outcome
Using the reported search, 47 papers were identified on Medline, 107 on Embase and five by hand-searching reference lists. Four papers provided the best evidence to -Cardiac output vs. 72"12 vs. 71"9 excluded from -cardiac output 4 lymin (CO) vs. 73"10 (Ps0.02 cohort -SVR-600 dyneysycm 5 -SVR at all post MB points -Norepinephrine vs. 0 h) Observational 0.5 mgykgymin study without -CO 7.6"3.1 lymin vs.
control group 2 mgykg MB administered 6.5"2.8 vs. 6.1"2.4 over 20 min in addition to vs. 5.8"1. answer the question and the author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and study commentsyweaknesses were tabulated. A further 14 papers were referenced to aid the discussion.
Results
In 1994, Gomes et al. identified a vasodilatory phenomenon in adult patients undergoing cardiac surgery utilizing cardiopulmonary bypass which was often refractory to highdose catecholamines and coined the phrase 'Vasoplegic Syndrome' (VPS) w2,3x. A similar syndrome has subsequently been identified in patients undergoing off-pump surgery w4x. As the condition has become better understood, novel treatment modalities have been described. One such treatment is methylene blue (MB) which is thought to act by inhibiting activation of soluble guanylate cyclase thus preventing formation of cylic guanosine 3959monophosphate (cGMP). cGMP has been shown to trigger vasodilatation and decreased myocardial contractility. The pathophysiology of VPS together with the pharmacology, dosage, pharmacokinetics and side-effects of MB, and some of the data supporting its use, has been discussed in detail in three recent reviews w5-7x (Table 1) .
Unfortunately, whilst using MB to treat VPS in adults was first described some 10 years ago, few good quality clinical studies have been performed. The first report in the literature was in 1996 when Andrade et al. described a series of six patients undergoing cardiac surgery with or without cardiopulmonary bypass who presented with profound hypotension unresponsive to high-dose catecholamines w8x. All responded to 1.5 mgykg MB by infusion with restoration of blood pressure and systemic vascular resistance without adverse effects on cardiac output or pulmonary vascular resistance. Since then a number of case reports have appeared describing MB use in VPS during complicated and uncomplicated cardiac surgery cases w9-16x.
Only three other cohort andyor RCTs have been performed. In 2003 Leyh et al. reported the use of MB in 54 non-endocarditis cardiac surgical patients who developed VPS noting a response rate to treatment of over 90% w17x. They demonstrated that administration of MB 2 mgykg led to significant increases in blood pressure and systemic vascular resistance in the first 12 h post-treatment. This was associated with a fall in cardiac output but changes in LAP, RAP and PAP were not significant. Levin et al. reported an incidence of VPS of 8.8% in 638 patients across four institutions in Argentina w18x. Mortality in their VPS group was three times that observed in their non-VPS patients. The 56 patients who developed VPS were subsequently randomized to receive MB 2 mgykg or placebo with all those receiving MB seeing resolution of VPS within 2 h. In contrast, 28.6% of their placebo group still required vasopressors at 48 h. Mortality in their placebo group was 28.6% compared to zero in their MB group with significantly higher incidences of sepsis and multi-system organ failure (Ps0.005) and trends towards higher incidences of renal failure, respiratory failure and myopathy (Ps0.05).
Finally, in 2005 Ozal assessed the effectiveness of MB as prophylaxis for VPS comparing it to a control in 100 patients deemed at high risk of VPS w19x. They demonstrated a highly significant lower incidence of VPS in their MB-treated group with significantly lower requirements for norepinephrine during CPB. Fluid requirements on CPB, inotropes during weaning from CPB, ITU stay and total hospital stay were all significantly less in their MB-treated group. Six of their control patients developed VPS refractory to norepinephrine, two of whom died. However, the criteria used in this study to define 'high-risk of VPS' were wide-ranging with limited supporting evidence for some factors and it is, therefore, debatable whether their population did represent a truly high-risk group.
Clinical bottom line
We conclude that MB may provide an interesting and novel therapeutic option for patients who develop catecholamine-resistant VPS during cardiac surgery. However, despite three recent reviews and a number of individual case reports, there are few large cohort or RCTs assessing its usefulness for this indication, although a recent study has suggested a possible prophylactic role in patients at high risk of VPS. Therefore, whilst it has a role as 'rescue therapy' for VPS, there is currently insufficient evidence to advocate its use as a first-line therapy. Further larger studies have to be performed before its routine use can be recommended.
